Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Cancer Monoclonal Antibodies Market Size & Share Analysis | Growth Trends and Forecasts (2026- 2031) | Covers Five Global Regions

globenewswire.com
BMY Mentioned for its acquisition of Mirati Therapeutics, indicating sustained industry investment in oncology pipelines and next-generation treatment platforms, contributing to market growth. LLY Mentioned for its acquisition of Point Biopharma, demonstrating sustained industry investment in oncology pipelines and next-generation treatment platforms, supporting market growth. AMGN Listed as a leading company in the cancer monoclonal antibodies market, indicating its presence and involvement in the sector. PFE Listed as a leading company in the cancer monoclonal antibodies market, indicating its presence and involvement in the sector. GSK Listed as a leading company in the cancer monoclonal antibodies market, indicating its presence and involvement in the sector. REGN Listed as a leading company in the cancer monoclonal antibodies market, indicating its presence and involvement in the sector. ABBV Listed as a leading company in the cancer monoclonal antibodies market, indicating its presence and involvement in the sector. SEIC Listed as a leading company in the cancer monoclonal antibodies market, indicating its presence and involvement in the sector. JNJ Listed as a leading company in the cancer monoclonal antibodies market, indicating its presence and involvement in the sector. AZN Listed as a leading company in the cancer monoclonal antibodies market, indicating its presence and involvement in the sector. MRK Listed as a leading company in the cancer monoclonal antibodies market, indicating its presence and involvement in the sector.

Cancer Monoclonal Antibodies Market Size & Share Analysis | Growth Trends and Forecasts (2026- 2031) | Covers Five Global Regions Dublin, Aug. 07, 2026 (GLOBE NEWSWIRE) -- The "Cancer Monoclonal Antibodies - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.

The global cancer monoclonal antibodies market is projected to expand from USD 92.89 billion in 2025 to USD 107.82 billion in 2026. The market is forecast to reach USD 227.16 billion by 2031, registering a compound annual growth rate (CAGR) of 16.07% from 2026 to 2031.

Market growth is being supported by the rising global incidence of cancer, increased investment in oncology research and development, and accelerating adoption of humanized, fully human, bispecific, and antibody-drug conjugate therapies. The report provides market forecasts by antibody source, monoclonal antibody therapy, cancer application, distribution channel, and geography, with estimates presented in USD.

Key Cancer Monoclonal Antibodies Market Trends

Global cancer incidence is expected to increase from 20 million cases in 2022 to approximately 35 million by 2050, representing a 77% rise. Aging populations, changing lifestyles, and growing cancer burdens across emerging economies are expanding demand for targeted oncology treatments. Lung, breast, colorectal, blood, and gastrointestinal cancers remain important therapeutic areas for monoclonal antibody development and commercialization.

Oncology continues to command a significant share of biopharmaceutical research and development spending. Approximately 35% of oncology clinical trials now involve antibody-drug conjugates or multispecific constructs. Major acquisitions, including Bristol Myers Squibb’s USD 5.8 billion purchase of Mirati Therapeutics and Eli Lilly’s USD 1.4 billion acquisition of Point Biopharma, demonstrate sustained industry investment in late-stage oncology pipelines and next-generation treatment platforms.

Stringent regulatory and safety requirements may moderate market expansion. Integrated safety data requirements for bispecific antibodies and antibody-drug conjugates, pediatric study obligations, comparative-effectiveness reviews, and European joint clinical assessments can increase development costs and extend approval timelines. These pressures are encouraging smaller biotechnology companies to pursue licensing agreements, strategic partnerships, and mergers with larger pharmaceutical organizations.

Additional market factors include:

Segment Analysis

Humanized antibodies accounted for 50.62% of market revenue in 2025, reflecting their established role in major oncology treatment regimens. Fully human antibodies are projected to record an 18.59% CAGR through 2031, supported by favorable safety profiles, lower immunogenicity, manufacturing advances, and increased use in combination protocols. Murine and chimeric formats are expected to retain roles in selected clinical settings but may lose share to newer antibody platforms.

Trastuzumab represented 16.72% of the cancer monoclonal antibodies market in 2025, supported by extensive clinical evidence and physician familiarity in HER2-positive breast cancer. However, therapies outside the leading established product categories are forecast to grow at 20.61% annually as antibody-drug conjugates and bispecific antibodies gain momentum. Approvals such as trastuzumab deruxtecan for HER2-low disease are also broadening eligible patient populations.

Regional Market Outlook

North America held 41.78% of global market revenue in 2025, driven by mature clinical trial infrastructure, favorable reimbursement conditions, extensive patient registries, and strong adoption of innovative oncology therapies. Patient-focused dosing options and growing use of real-world evidence are also supporting value-based treatment models across the region.

Asia-Pacific is forecast to achieve the fastest regional growth, with an 18.92% CAGR through 2031. Rising oncology budgets, aging populations, accelerated regulatory pathways, expanding commercial health insurance, and investment in domestic biomanufacturing are strengthening the regional cancer monoclonal antibodies market.

Europe is advancing coordinated clinical assessments while maintaining strong adoption of oncology biosimilars. The Middle East, Africa, and South America are expected to generate additional opportunities as governments prioritize cancer treatment, attract pharmaceutical investment, expand local fill-and-finish capacity, and implement patient assistance and flexible pricing programs.

Report Scope

Companies Covered in the Cancer Monoclonal Antibodies Market Report

Leading companies covered include Roche, Merck, Bristol Myers Squibb, Amgen, Novartis, Johnson & Johnson, AstraZeneca, Eli Lilly and Company, Pfizer, GlaxoSmithKline, Regeneron Pharmaceuticals, AbbVie, Seagen, Daiichi Sankyo, Sanofi, Genmab, BeiGene, Spectrum Pharmaceuticals, Mitsubishi Tanabe Pharma, and WuXi Biologics.

The report also includes a market estimate sheet in Excel format and three months of analyst support.

For more information about this report visit https://www.researchandmarkets.com/r/ggqq4s

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.